抗PD-1单抗联合安罗替尼治疗晚期食管癌的近期疗效观察

Observation on the short-term efficacy of anti-PD-1 monoclonal antibody combined with anlotinib in the treatment of advanced esophageal cancer

目的观察抗程序性死亡受体-1(PD-1)单抗联合安罗替尼治疗晚期食管癌的近期疗效及安全性。方法13例晚期食管癌患者,均采用抗PD-1单抗(特瑞普利单抗注射液)联合安罗替尼治疗,观察治疗效果及不良反应发生情况。结果13例患者中,完全缓解(CR)1例,部分缓解(PR)3例,疾病稳定(SD)6例,疾病进展(PD)3例,客观缓解率(ORR)为30.8%,疾病控制率(DCR)为76.9%。出现手足皮肤反应3例(23.1%),转氨酶升高2例(15.4%),乏力3例(23.1%),高血压2例(15.4%),消化道反应4例(30.8%),白细胞下降2例(15.4%),咳血1例(7.7%),甲状腺功能异常1例(7.7%)。患者均可耐受,经治疗后好转或缓解。无治疗相关死亡病例。结论抗PD-1单抗联合安罗替尼在晚期食管癌中具有良好的疾病控制率,同时耐受性良好,为临床提供了新的治疗策略。

Objective To observe the short-term efficacy and safety of anti-programmed death(PD)-1 monoclonal antibody combined with anlotinib in the treatment of advanced esophageal cancer.Methods 13 patients with advanced esophageal cancer were all treated with anti-PD-1 monoclonal antibody(toripalimab injection)and anlotinib,and the therapeutic effect and the occurrence of adverse reactions were observed.Results Among the 13 patients,1 case was complete remission(CR),3 cases were partial remission(PR),6 cases were stable disease(SD),and 3 cases were progressive disease(PD),with an objective remission rate(ORR)of 30.8%and a disease control rate(DCR)of 76.9%.There were 3 cases(23.1%)of hand-foot skin reaction,2 cases(15.4%)of elevated transaminase,3 cases(23.1%)of fatigue,2 cases(15.4%)of hypertension,4 cases(30.8%)of gastrointestinal reactions,and 2 cases(15.4%)of decreased white blood cells,1 case(7.7%)of hemoptysis,and 1 case(7.7%)of abnormal thyroid function.All patients could tolerate it and get better or relieved after treatment.There were no treatment-related deaths.Conclusion Anti-PD-1 monoclonal antibody combined with anlotinib has a good disease control rate and good tolerance in advanced esophageal cancer,and it provides a new clinical treatment strategy.